ABSTRACT
Photosafety testing is of concern for the evaluation of personal care products and pharmaceuticals. Current regulatory guidance state that photosafety should be evaluated for compounds that absorb radiation between 290 and 700 nm with relevant exposure in the skin or eyes. However, oversensitivity and the occurrence of 'pseudo-effects' with current in vitro photo(geno)toxicity assays have become a major problem. Furthermore, at this moment, there are no relevant in vitro assays available to identify the photocarcinogenic potential of compounds, which might result in unnecessary in vivo photocarcinogenicity studies for pharmaceutical ingredients or unnecessary dropouts in the development of ingredients of personal care products. For these reasons, availability of a relevant and highly predictive in vitro model from human origin to identify the photogenotoxic and/or photocarcinogenic potential of compounds is viewed as high priority. In the present study, human skin tissue obtained from surgery was used for developing a photomicronucleus test. Prior to investigations of the photogenotoxic potential of 8-methoxypsoralen, tissue viability (lactate production and lactate dehydrogenase leakage), cell proliferation (Ki-67 expression) and the effect of ultraviolet (UV) exposure on viability (MTT test), proliferation (Ki-67 expression) and p53 expression were determined. Results of the present study indicate that ex vivo human skin seems to be a relevant method for safety evaluation of compounds that reach the skin in combination with UV exposure.
Subject(s)
Drug Industry/methods , Skin , Adult , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Cell Survival/drug effects , Cell Survival/radiation effects , Female , Gene Expression Regulation/radiation effects , Humans , Ki-67 Antigen/metabolism , Male , Methoxsalen/toxicity , Micronuclei, Chromosome-Defective , Micronucleus Tests , Middle Aged , Reproducibility of Results , Sensitivity and Specificity , Skin/drug effects , Skin/radiation effects , Time Factors , Tumor Suppressor Protein p53/metabolism , Ultraviolet RaysABSTRACT
For pharmaceuticals, current regulatory guidance for photosafety testing states that studies are warranted for drug candidates that both absorb light in the range of 290-700 nm and that are either applied topically or reach the skin or eyes by systemic exposure. In contrast to standard genotoxicity evaluations, where a positive (or equivocal) result in vitro can be placed into context with additional testing in vivo, there are no equivalent short-term in vivo photogenotoxicity assays in the current photosafety test battery. Therefore, a short-term in vivo assay for the evaluation of a photogenotoxic potential in the skin, the target organ for photocarcinogenicity, was developed in rats. After oral 8-methoxypsoralen administration, rats were exposed to ultraviolet radiation and sacrificed 3 days after treatment to isolate epidermal cells for subsequent micronucleus (MN) evaluation. Optimal conditions were determined to obtain maximal induction of MN, followed by demonstrating feasibility and reproducibility of the method. The results of the present study indicate that the in vivo rat skin photomicronucleus test may be a promising tool for detection of photoclastogenicity. Given the association between MN induction and cancer, the assay may also provide a promising tool for the early detection of photocarcinogenesis and help bridge the gap in the existing photosafety testing paradigm.
